Landmark Studies on Response and Survival in Liver Malignancies
| Study | Design | Tumor | Treatment | Patients (n) | Response criteria | CR (%) | PR (%) | SD (%) | PD (%) | TTHP (mo) | MS (mo) |
| Kolligs (60) | Pilot randomized controlled trial | HCC; BCLC A–C; Child–Pugh ≤ B7 | RE | 13 | RECIST 1.0 | 0 | 30.8 | 46.2 | 15.4 | 3.7 | NA |
| CE | 15 | 0 | 13.3 | 60.0 | 20.0 | 3.6 | NA | ||||
| Gramenzi (62) | Single-center, prospective cohort | HCC; BCLC B–C; Child–Pugh ≤ B7 | RE | 63 | mRECIST | 14.3 | 53.9 | 14.3 | 17.5 | 3 | 13.2 |
| 62.5 | 18.8 | 18.7 | 3 | 11.2 | |||||||
| Sorafenib | 73 | 0 | 9.5 | 41.9 | 48.6 | 5 | 14.4 | ||||
| 9.4 | 37.5 | 53.1 | 3 | 13.1 | |||||||
| Al-Adra (72) | Systematic review | Intrahepatic cholangiocarcinoma | RE | 298 | Pooled analysis | 0 | 28 | 54 | 18 | NA | 15.5 |
| Devcic (77) | Metaanalysis | Neuroendocrine tumor | RE | 435 | Pooled analysis | 50 | 36 | 14 | NA | 28.5 | |
| Saxena (67) | Systematic review | Metastatic colorectal cancer | RE | 979 | Pooled analysis | 0 | 31 | 40.5 | 17.5 | 9 | 12 |
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; TTHP = median time to hepatic progression; MS = median survival; RE = radioembolization; NA = not available; CE = chemoembolization.
Italicized numbers are confounder-corrected results. Boldface numbers are data for CR and PR combined.